Product Pipeline for New Pharmaceutical Drugs

OUR MEDICINES IN DEVELOPMENT

Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients. 

Pipeline Snapshot as of November 2, 2021

  • Discovery Projects
  • Phase 1
    27
  • Phase 2
    29
  • Phase 3
    29
  • Registration
    9
  • Total94
Therapeutic Area
Submission Type
Compound Type
Phase of Development
Compound NameIndicationPhaseSubmission TypeCompound Type
Comirnaty (Covid-19 Vx)
Therapeutic Area:
Vaccines
Phase:Registration
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic mRNA Vaccine
COVID-19 Infection (in collaboration with BioNTech)(FAST TRACK, U.S. - 12 to 15 years of age) (E.U. - 12 years of age and older) Registration Product Enhancement Vaccine
Comirnaty (Covid-19 Vx)
Therapeutic Area:
Vaccines
Phase:Registration
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic mRNA Vaccine
COVID-19 Infection Booster (in collaboration with BioNTech)(FAST TRACK, U.S.; EU)
Project advanced
Registration Product Enhancement Vaccine
Comirnaty (Covid-19 Vx)
Therapeutic Area:
Vaccines
Phase:Registration
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic mRNA Vaccine
COVID-19 Infection (in collaboration with BioNTech)(FAST TRACK, U.S.; EU - 5 to 11 years of age)
Project advanced
Registration Product Enhancement Vaccine
PF-06482077
Therapeutic Area:
Vaccines
Phase:Registration
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Invasive and Non-Invasive Pneumococcal infections (adult) (E.U.) Registration New Molecular Entity Vaccine
PF-06425090
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Primary Clostridioides difficile infection (FAST TRACK) Phase 3 New Molecular Entity Vaccine
PF-06482077
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Invasive and Non-Invasive Pneumococcal infections (pediatric) (BREAKTHROUGH, FAST TRACK) Phase 3 Product Enhancement Vaccine
PF-06928316
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Respiratory Syncytial Virus Infection (maternal) (FAST TRACK) Phase 3 New Molecular Entity Vaccine
PF-06886992
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Serogroups ABCWY Meningococcal Infections (adolescent and young adults) Phase 3 New Molecular Entity Vaccine
PF-06928316
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Respiratory Syncytial Virus Infection (older adult)
Project advanced
Phase 3 Product Enhancement Vaccine
Comirnaty (Covid-19 Vx)
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic mRNA Vaccine
COVID-19 Infection (in collaboration with BioNTech) (maternal)
Project advanced
Phase 3 Product Enhancement Vaccine
Comirnaty (Covid-19 Vx)
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic mRNA Vaccine
COVID-19 Infection (in collaboration with BioNTech) (children 2 to 4?years of age)
Project advanced
Phase 3 Product Enhancement Vaccine
Comirnaty (Covid-19 Vx)
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic mRNA Vaccine
COVID-19 Infection (in collaboration with BioNTech) (infants 6 months to <24 months)
Project advanced
Phase 3 Product Enhancement Vaccine
PF-06842433
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Invasive and Non-Invasive Pneumococcal infections (infants and children) Phase 2 New Molecular Entity Vaccine
PF-06760805
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Invasive Group B Streptococcus Infection (maternal) (FAST TRACK) Phase 2 New Molecular Entity Vaccine
PF-07307405
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Lyme disease (FAST TRACK) Phase 2 New Molecular Entity Vaccine
PF-06886992
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Serogroups ABCWY Meningococcal Infections (infants) Phase 2 Product Enhancement Vaccine
PF-07252220
Therapeutic Area:
Vaccines
Phase:Phase 1
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic mRNA Vaccine
Influenza (adults)
Project advanced
Phase 1 New Molecular Entity Vaccine
Lorbrena (lorlatinib)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
ALK inhibitor
1st Line ALK Non-Small Cell Lung Cancer (E.U.) Registration Product Enhancement Small Molecule